The FDA has granted Fast Track Designation to the imaging agent 99 mTc-maraciclatide for endometriosis diagnosis, which could revolutionize women’s healthcare. Developed by Serac Healthcare, this technology aims to provide a non-invasive and reliable test for the condition, reducing the average seven and a half year delay in diagnosis. The Fast Track process will prioritize the application for use in imaging of superficial endometriosis, potentially leading to accelerated approval. This innovative approach offers a new strategy for diagnosing endometriosis without the need for surgery, with promising results from phase II clinical trials. Endometriosis affects millions of women worldwide and a more efficient diagnostic tool could significantly improve patient experience.
Source link
Endometriosis Update: FDA Fast Tracks Diagnostic Imaging for Superficial Endometriosis
